Patents by Inventor Malin Lindborg
Malin Lindborg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210401930Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: ApplicationFiled: September 20, 2021Publication date: December 30, 2021Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Publication number: 20210403533Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX2X3X4X5X6X7EIX10X11LPNLX16RX18QYX21AFIX25X26LX28D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.Type: ApplicationFiled: April 3, 2018Publication date: December 30, 2021Inventors: Joachim Feldwisch, Malin Lindborg, Joakim Nilsson, Erik Nordling, Robert Svensson
-
Patent number: 11123401Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: GrantFiled: December 20, 2018Date of Patent: September 21, 2021Assignee: IPC Research, LLCInventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Publication number: 20200199197Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29 (SEQ ID NO:1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: January 15, 2020Publication date: June 25, 2020Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 10562955Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: December 14, 2017Date of Patent: February 18, 2020Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20190284241Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: April 8, 2019Publication date: September 19, 2019Inventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Patent number: 10323066Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: September 17, 2015Date of Patent: June 18, 2019Assignee: AFFIBODY ABInventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Publication number: 20190167760Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: ApplicationFiled: December 20, 2018Publication date: June 6, 2019Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 10206975Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: GrantFiled: September 29, 2017Date of Patent: February 19, 2019Assignee: Swedish Orphan Biovitrum AB (PUBL)Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 9975943Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: March 17, 2014Date of Patent: May 22, 2018Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20180118807Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: December 14, 2017Publication date: May 3, 2018Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Publication number: 20180085428Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.Type: ApplicationFiled: September 29, 2017Publication date: March 29, 2018Applicant: Swedish Orphan Biovitrum AB (publ)Inventors: Charlotta Berghard, Magnus Berglund, Patrick Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 9873729Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: GrantFiled: March 17, 2014Date of Patent: January 23, 2018Assignee: AFFIBODY ABInventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 9808502Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.Type: GrantFiled: February 19, 2013Date of Patent: November 7, 2017Assignee: Swedish Orphan Biovitrum AB (publ)Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Publication number: 20170260238Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein said first and second monomer unit search comprises an FcRn binding motif. Said FcRn binding dimer binds FcRn with higher capacity compared to said first monomer unit or second monomer unit alone. The present disclosure also relates to the use of said FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: September 17, 2015Publication date: September 14, 2017Applicant: Affibody ABInventors: Lars Abrahmsén, Caroline Ekblad, Elin Gunneriusson, Torbjörn Gräslund, Johan Seijsing, John Löfblom, Malin Lindborg, Fredrik Frejd, Lindvi Gudmundsdotter
-
Publication number: 20160031967Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.Type: ApplicationFiled: March 17, 2014Publication date: February 4, 2016Inventors: Caroline Ekblad, Elin Gunneriusson, Malin Lindborg, Lars Abrahmsen, John Löfblom, Torbjörn Gräslund, Johan Seijsing
-
Patent number: 9187535Abstract: The invention provides a platelet derived growth factor receptor beta (PDGF-R?) binding polypeptide, comprising a platelet derived growth factor receptor beta binding motif, PBM, which motif consists of an amino acid sequence as defined herein, wherein the PDGF-R?-binding polypeptide binds to PDGF-R? such that the KD value of the interaction is at most 1×10?6 M. Also provided are methods and uses of said polypeptide in treatment and diagnosis of PDGF-R?-related conditions.Type: GrantFiled: December 17, 2008Date of Patent: November 17, 2015Assignee: AFFIBODY ABInventors: Malin Lindborg, Elin Gunneriusson, Christofer Lendel
-
Patent number: 8937047Abstract: Provided herein are methods of reducing liver uptake in vivo of a polypeptide that specifically binds to a target comprising: (a) providing a polypeptide that specifically binds to a target; and (b) substituting at least one basic or at least one neutral amino acid residue of the native polypeptide from step (a) with an acidic amino acid residue to produce a modified polypeptide, wherein the modified polypeptide demonstrates an isoelectric point at least 0.05-0.1 pH points less than the isoelectric point of the native polypeptide. Also provided are polypeptides made using the inventive methods as well as imaging techniques that employ the methods and agents.Type: GrantFiled: December 19, 2007Date of Patent: January 20, 2015Assignee: General Electric CompanyInventors: Michael Ernest Marino, Faisal Ahmed Syud, Jason William Castle, Brian Duh-Lan Lee, Malin Lindborg, Elin Gunneriusson, Christofer Lendel
-
Publication number: 20150011474Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX23X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.Type: ApplicationFiled: February 19, 2013Publication date: January 8, 2015Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Patent number: 8124725Abstract: Provided herein are PDGF-R? imaging agents that are polypeptides labeled with a signal generator (e.g., paramagnetic label, a radionuclide, or a fluorophore), wherein the imaging agents bind specifically to PDGFR-?. Also provided are in vivo imaging methods using the imaging agents.Type: GrantFiled: December 17, 2008Date of Patent: February 28, 2012Assignee: General Electric CompanyInventors: Michael Ernest Marino, Faisal Ahmed Syud, Paul Schaffer, Brian Duh-Lan Lee, Rong Zhang, Malin Lindborg, Elin Gunneriusson, Christopher Lendel